Aktsia Ligand Pharmaceuticals Inc (LGDN) hind ja uudised

Sümbolid Sümbolid	Hind	Muutus	% muutus	Trend	Eelm. sulgemishind	Ava	Kõrge	Madal	Maht	Turu kapit.
SIXB Materials SIXB Materials	SIXB +0,25%	1 104,10	+2,73	+0,25%	—	1 101,37	1 103,63	1 105,31	1 091,41	—	—
SIXC Communications SIXC Communications	SIXC −1,50%	604,16	−9,19	−1,50%	—	613,35	613,35	613,35	601,49	—	—
SIXE Energy SIXE Energy	SIXE −0,09%	1 197,81	−1,02	−0,09%	—	1 198,83	1 199,68	1 199,75	1 182,41	—	—
SIXI Industrials SIXI Industrials	SIXI −0,88%	1 740,41	−15,54	−0,88%	—	1 755,95	1 754,06	1 756,03	1 734,69	—	—
SIXM Financials SIXM Financials	SIXM −0,64%	634,44	−4,07	−0,64%	—	638,51	637,41	637,41	633,05	—	—
SIXR Staples SIXR Staples	SIXR −0,31%	840,90	−2,62	−0,31%	—	843,52	843,35	846,40	837,93	—	—
SIXRE Real estate SIXRE Real estate	SIXRE −0,38%	215,13	−0,82	−0,38%	—	215,95	215,95	216,84	215,06	—	—
SIXT Technology SIXT Technology	SIXT +2,86%	3 228,71	+89,80	+2,86%	—	3 138,91	3 189,30	3 230,85	3 174,76	—	—
SIXU Utilities SIXU Utilities	SIXU +0,16%	935,87	+1,50	+0,16%	—	934,37	934,72	938,26	927,50	—	—
SIXV Health care SIXV Health care	SIXV −1,37%	1 457,12	−20,31	−1,37%	—	1 477,43	1 474,12	1 474,12	1 451,80	—	—
SIXY Discretionary SIXY Discretionary	SIXY +0,83%	2 399,84	+19,65	+0,83%	—	2 380,19	2 389,34	2 403,04	2 380,47	—	—

LGDN:FRA

Ligand Pharmaceuticals Inc

190,00 €

0,00%

(0,00) 1 p

24. apr, 22:00:00 GMT +2 · EUR

Kõik sümbolid

1 p

5 p

1 kuu

6 kuud

YTD

1 a

5 a

MAX

	Sümbol	Hind	Muutus	% muutus

Üksuse LGDN põhistatistika genereerimine…

Ava

192,00 €

Kõrge

192,00 €

Madal

190,00 €

Turu kapit.

4,63 mld

Keskm. maht

3,00

Maht

0,00

52 näd kõrgeim

195,00 €

52 näd madalaim

87,00 €

Töötajate arv

Uudised

Erinevatest veebiallikatest

The Motley Fool

7 minuti eest

The Nasdaq Is Approaching All-Time Highs. Is It Too Late to Buy These Artificial Intelligence (AI) Growth Stocks?

Crypto Briefing

34 minuti eest

S&P 500 companies cut 400,000 jobs in 2025, first decline since 2016

Yahoo Finance

1 tunni eest

S&P 500 Is Overbought—But JPMorgan Says The Rally Isn't Done Yet

MSN

1 tunni eest

The stock market recently did something witnessed only once before in 154 years -- and history is very clear about what happens next

Profiil

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia

Teave üksuse Ligand Pharmaceuticals Inc kohta

Tegevjuht-

Töötajad47

Asutatudsept 1987

PeakontoridJupiter, Florida, Ameerika Ühendriigid

Sektor-

Veebisaitligand.com

Kõik väärtused on valuutas USD	märts 2025	juuni 2025	sept 2025	dets 2025
Tulu	45,33 mln	47,63 mln	115,46 mln	59,67 mln
Omahind	54,93 mln	9,47 mln	24,82 mln	6,50 mln
Kogukulu	54,93 mln	9,47 mln	24,82 mln	6,50 mln
Teadus- ja arenduskulud	-	-	-	-
Kõik teadus- ja arenduskulud	-	-	-	-
Müügi-, üld- ja halduskulud	18,80 mln	20,18 mln	28,45 mln	25,03 mln
Tegevuskulu	27,06 mln	28,43 mln	36,54 mln	33,12 mln
Kõik tegevuskulud	81,99 mln	37,91 mln	61,36 mln	39,63 mln
Tegevustulu	−36,66 mln	9,72 mln	54,10 mln	20,04 mln
Muu tegevusväline tulu	−2,06 mln	96,00 tuh	390,00 tuh	1,48 mln
EBT, sh ebatavalised üksused	−50,18 mln	11,22 mln	141,14 mln	56,78 mln
EBT, v.a ebatavalised üksused	−37,81 mln	10,28 mln	57,45 mln	116,80 mln
Tulumaksukulu	−7,73 mln	6,38 mln	23,86 mln	12,00 mln
Kehtiv maksumäär	15,40%	56,81%	16,91%	21,13%
Muud tegevuskulud	-	-	-	-
Netosissetulek	−42,45 mln	4,85 mln	117,27 mln	44,78 mln
Puhaskasumi marginaal	−93,64%	10,18%	101,57%	75,06%
Aktsiatulu	1,33	1,60	3,09	2,02
Intressi- ja investeerimistulu	1,77 mln	1,62 mln	3,87 mln	6,39 mln
Intressikulu	−867,00 tuh	−1,15 mln	−910,00 tuh	−1,78 mln
Netointressikulud	904,00 tuh	468,00 tuh	2,96 mln	4,61 mln
Kulum ja amortisatsiooni kulud	-	-	-	-
EBITDA	−28,35 mln	17,82 mln	63,26 mln	28,25 mln
Kasum või kahjum varade müügist	-	-	-	-

AI genereeritud sisu võib sisaldada vigu. Lisateave

AbiSaada tagasisidetPrivaatsus Tingimused Lahtiütlus

Finance

Uuring